Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-10529
- Development stage
- Phase 1
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HS-10529 is an **oral, highly selective small molecule inhibitor** specifically designed to target the KRAS G12D mutation. It is being developed as a therapy for **advanced solid tumors** harboring KRAS G12D mutations, including cancers such as pancreatic cancer, colorectal cancer, and non-small cell lung cancer. Preclinical studies have demonstrated favorable pharmacodynamics, pharmacokinetics, and safety. It is currently being evaluated in a **phase 1 clinical trial** for safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors that are refractory to standard therapies. HS-10529 is self-developed by Hansoh Pharmaceutical[1][2][4][5][7][10].
02
Targets
KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)
Beyond the preview
Go deeper on HS-10529.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-10529.